Merck's chief science and technology officer Laura Matz said that Innerva's platform could become "a true enabler for digital personalised treatment of patients suffering from severe and chronic ...
“Digitalisation is key to our long-term growth strategy,” commented Laura Matz, chief science and technology officer of Merck, who noted the DevTools provide consistent digital ‘blueprints ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback